

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT 		Application Number	10/023,636
		Filing Date	December 17, 2001
		First Named Inventor	Furman <i>et al.</i>
		Group Art Unit	1623
		Examiner Name	N/A
		Attorney Docket Number	04674.105068
		of	2

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
D	BA	BATTAGLIA, A.M. <i>et al.</i> "Combination Therapy with Interferon and Ribavirin in the Treatment of Chronic Hepatitis C Infection." <i>Ann. Pharmacother.</i> 34:487-494, April 2000.	
U	BB	BERENGUER, M. <i>et al.</i> "Hepatitis C Virus in the transplant setting." <i>Antivir. Ther.</i> 3(Suppl. 3):125-136, 1998.	
G	BC	DAVIS, G.L. "Current Therapy for Chronic Hepatitis C." <i>Gastroenterology.</i> 118: S104-S114, February 2000.	
D	BD	HEREDIA, A., <i>et al.</i> "Abacavir in Combination with the IMPDH-Inhibitor Mycophenolic Acid is Active Against Multidrug-Resistant HIV-1." <i>J. Acquir. Immune Defic. Syndr.</i> 22(4):406-407, December 1, 1999.	
D	BE	KIM, H.O., <i>et al.</i> "Potent anti-HIV and anti-HBV Activities of (-)-L-β-Dioxolane-C and (+)-L-β-Dioxolane-T and Their Asymmetric Syntheses." <i>Tetrahedron Letters.</i> 32(46):5899-6902, 1992.	
D	BF	MARGOLIS, D.M., <i>et al.</i> "Abacavir and Mycophenolic Acid, an Inhibitor of Inosine Monophosphate Dehydrogenase, Have Profound and Synergistic Anti-HIV Activity." <i>J. Acquir. Immune. Defic. Syndr.</i> 21(5):362-370, August 15, 1999.	
U	BG	NORBECK, <i>et al.</i> , "A New 2',3'-Dideoxynucleoside Prototype with <i>In Vitro</i> Activity Against HIV." <i>Tetrahedron Letters</i> , 30(46):6263-66, 1989.	
U	BH	SIDDIQUI, <i>et al.</i> , "Antiviral Optically Pure Dioxolane Purine Nucleoside Analogues." <i>Bioorganic & Medicinal Chemistry Letters.</i> 3(8):1543-1546, 1993.	
U	BI	WEISLOW, O.S., <i>et al.</i> "New Soluble-Formazan Assay for HIV-1 Cytopathic Effects: Application to High-Flux Screening of Synthetic and Natural Products for AIDS-Antiviral Activity." <i>J. of NCI.</i> 81(8):577-586, April 19, 1989.	

Examiner Signature		Date Considered	6/24/03
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.


Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT 				Application Number	10/023,636
				Filing Date	December 17, 2001
				First Named Inventor	Furman <i>et al.</i>
				Group Art Unit	1623
				Examiner Name	N/A
				Attorney Docket Number	04674.105068
Sheet of 2					

U.S. PATENT DOCUMENTS						
Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
5	AA	RE 29,835		Witkowski <i>et al.</i>	11-14-1978	
5	AB	3,798,209		Witkowski <i>et al.</i>	03-19-1974	
5	AC	4,686,234		Nelson <i>et al.</i>	08-11-1987	
5	AD	5,041,449		Belleau <i>et al.</i>	08-20-1991	
5	AE	5,179,104		Chu <i>et al.</i>	01-12-1993	
5	AF	5,270,315		Belleau <i>et al.</i>	12-14-1993	
5	AG	5,444,063		Schinazi	08-22-1995	
5	AH	5,665,728		Morris <i>et al.</i>	09-09-1997	
5	AI	5,684,010		Schinazi	11-04-1997	
5	AJ	5,767,122		Chu <i>et al.</i>	06-16-1998	
5	AK	5,830,898		Schinazi	11-03-1998	
5	AL	5,834,474		Schinazi	11-10-1998	
5	AM	5,925,643		Chu	07-20-1999	

FOREIGN PATENT DOCUMENTS								
Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document DD-MM-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number	Kind Code ² (if known)				
5	AN	EP	0 337 713		Belleau <i>et al.</i>	18-10-1989		
5	AO	EP	0 515 156		Mansour <i>et al.</i>	24-11-1992		

Examiner Signature		Date Considered	6/14/03
-----------------------	---	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.